IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences

Giudicelli, Véronique; Brochet, Xavier; Lefranc, Marie‐Paule

doi:10.1101/pdb.prot5633

Cited by 270 publications

(306 citation statements)

References 36 publications

Supporting

Mentioning

304

Contrasting

Unclassified

Order By: Relevance

“…Antibody variable gene sequence analysis was performed as previously described (39). Heavy and light chain antibody variable region sequences were analyzed using the IMGT/V-Quest program (51,52).…”

Section: Methodsmentioning

confidence: 99%

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

et al. 2017

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

et al. 2017

View full text Add to dashboard Cite

“…The homoduplex bands were excised and purified from the polyacrylamide gel and further sequenced using the DYEnamic ET Terminator Cycle Sequencing Kit (GE Healthcare, formerly Amersham Biosciences, Chalfont St. Giles, UK) on an ABI 310 Automated Sequencer (Applied Biosystems, Foster City, CA) or BigDye 1 Terminator v3.1 Cycle Sequencing Kit on an ABI 3100 Automated Sequencer (LifeTechnologies, formerly Applied Biosystems, Foster City, CA). The sequences obtained were identified using IMGT/V-QUEST software (http://www.IMGT.org/ IMGT_vquest/share/textes/) [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

Rossi¹,

Bernasconi²,

Alonso³

et al. 2012

American J Hematol

125

114

View full text Add to dashboard Cite

Although rarely, switches between lymphoid and myeloid lineages may occur during treatment of acute leukemias (AL). Correct diagnosis relies upon confirmation by immunophenotyping of the lineage conversion and certification that the same cytogenetic/molecular alterations remain despite the phenotypic changes. From a total of 1,482 AL pediatric patients, we report nine cases of lineage conversion (0.6%), seven from lymphoid (four Pro-B, two Pre-B, one Common) to myelo-monocytic, and two from myeloid (bilineal, with myeloid predominance) to Pro-B. Eight patients were infants. Switches were suggested by morphology and confirmed with a median of 15 days (range: 8 days-6 months) from initiation of therapy. Of note, in five cases switches occurred before day 15. Stability of the clonal abnormalities was assessed by cytogenetic, RT-PCR/Ig-TCR rearrangement studies in all patients. Abnormalities in 11q23/MLL gene were detected in seven cases. Treatment schedules were ALL (two pts), Interfant-99 (five pts) and AML (two pts) protocols. Despite changing chemotherapy according to the new lineage, all patients died. Our findings support the association of lineage switches with MLL gene alterations and the involvement of a common lymphoid B-myeloid precursor. New therapies should be designed to address these rare cases. Possible mechanisms implicated are discussed. Am. J. Hematol. 87:890-897, 2012. V

show abstract

“…PCR fragments were sequenced using the same VH family primer used for amplification. Sequences were analyzed using IgBlast 23 and International ImMunoGeneTics (IMGT) V-Quest, [24][25][26] and IgH V, D, and J genes with highest significance in both analyses are shown in Table 1.…”

Section: Genescan and Cdr3 Analysismentioning

confidence: 99%

B-cell tumor development in Tet2-deficient mice

et al. 2018

View full text Add to dashboard Cite

Key Points• Tet2 is a tumor suppressor in B cells.• Loss of Tet2 in B cells leads to age-dependent transformation that requires AID.The TET2 gene encodes an a-ketoglutarate-dependent dioxygenase able to oxidize 5-methylcytosine into 5-hydroxymethylcytosine, which is a step toward active DNA demethylation. TET2 is frequently mutated in myeloid malignancies but also in B-and Tet2-Aicda-deficient mice. Finally, we show that Tet2 deficiency accelerates and exacerbates T-cell leukemia/lymphoma 1A-induced leukemogenesis. Together, our data establish thatTet2 deficiency predisposes to mature B-cell malignancies, which development might be attributed in part to AID-mediated accumulating mutations and BCR-mediated signaling.

show abstract

IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences

Cited by 270 publications

References 36 publications

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

B-cell tumor development in Tet2-deficient mice

Contact Info

Product

Resources

About